179 related articles for article (PubMed ID: 8137645)
1. [Relation between DNA content in ovarian cystadenoma and its pathohistology].
Sun ZC
Zhonghua Fu Chan Ke Za Zhi; 1993 Dec; 28(12):731-3, 760-1. PubMed ID: 8137645
[TBL] [Abstract][Full Text] [Related]
2. [A quantitative study on nuclear DNA content and morphological parameters in ovarian cystadenocarcinoma].
Liu C; Zhao Y; Sun X
Zhonghua Fu Chan Ke Za Zhi; 1995 Dec; 30(12):738-40. PubMed ID: 8728920
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic significance of cellular DNA content and AgNOR count in ovarian cystadenoma].
Lu XL; Yi WM; Wang LF
Ai Zheng; 2003 Jan; 22(1):62-5. PubMed ID: 12561439
[TBL] [Abstract][Full Text] [Related]
4. Flow cytometry and AgNORs in benign, borderline, and malignant mucinous and serous tumours of the ovary.
Griffiths AP; Cross D; Kingston RE; Harkin P; Wells M; Quirke P
Int J Gynecol Pathol; 1993 Oct; 12(4):307-14. PubMed ID: 8253547
[TBL] [Abstract][Full Text] [Related]
5. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
6. A study of the methylation status of opioid binding protein/cell adhesion molecule-like gene in ovarian cancer using nested methylation-specific polymerase chain reaction detection.
Zhou F; Cao X; Liu M; Wang Y; Tao G
Clin Lab; 2011; 57(5-6):421-4. PubMed ID: 21755835
[TBL] [Abstract][Full Text] [Related]
7. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S
Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214
[TBL] [Abstract][Full Text] [Related]
8. Association of decreased mitochondrial DNA content with ovarian cancer progression.
Wang Y; Liu VW; Xue WC; Cheung AN; Ngan HY
Br J Cancer; 2006 Oct; 95(8):1087-91. PubMed ID: 17047655
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC
Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344
[TBL] [Abstract][Full Text] [Related]
10. [Accuracy of frozen section in diagnosis of ovarian tumors].
Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 1993 Oct; 28(10):601-3, 635. PubMed ID: 8112130
[TBL] [Abstract][Full Text] [Related]
11. [Tumor necrosis factor gene expression in ovarian tumor].
Gao SF; Zhang SZ; Zhang MH
Zhonghua Fu Chan Ke Za Zhi; 1994 Jul; 29(7):389-91, 443. PubMed ID: 8001412
[TBL] [Abstract][Full Text] [Related]
12. Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers.
Dion F; Mes-Masson AM; Seymour RJ; Provencher D; Tonin PN
Oncogene; 2000 Mar; 19(11):1466-72. PubMed ID: 10723138
[TBL] [Abstract][Full Text] [Related]
13. Expression of c-myc and mutation of the KRAS gene in patients with ovarian mucinous tumors.
Li XS; Sun J; He XL
Genet Mol Res; 2015 Sep; 14(3):10752-9. PubMed ID: 26400304
[TBL] [Abstract][Full Text] [Related]
14. DNA flow cytometric evaluation of serous and mucinous cystic neoplasms of the pancreas.
Unger PD; Danque PO; Fuchs A; Kaneko M
Arch Pathol Lab Med; 1991 Jun; 115(6):563-5. PubMed ID: 2039342
[TBL] [Abstract][Full Text] [Related]
15. [Mural nodules of anaplastic carcinoma in bilateral ovarian borderline mucinous cystadenoma: a case report].
Guilbeau C; Soubeyrand MS; Devillebichot C; Sage M; Collin F; Arnould L
Ann Pathol; 2003 Sep; 23(4):340-4. PubMed ID: 14597898
[TBL] [Abstract][Full Text] [Related]
16. [Significance and mechanisms of overexpression of PAK1 gene in epithelial ovarian neoplasms].
Xie D; Yang GF; Chen YQ; Jiang LF; Xiao LZ
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):911-4. PubMed ID: 17533742
[TBL] [Abstract][Full Text] [Related]
17. Serous and mucinous borderline ovarian tumors: are there real differences between these two entities?
Benito V; Lubrano A; Arencibia O; Medina N; Álvarez Eva E; Andújar M; Falcón Juan M; Falcón O
Eur J Obstet Gynecol Reprod Biol; 2010 Dec; 153(2):188-92. PubMed ID: 20728981
[TBL] [Abstract][Full Text] [Related]
18. [Expressions of Cx43 and Skp2 in epithelial ovarian tumor and their clinical significances].
Hu YQ; Liu YJ
Ai Zheng; 2005 Jan; 24(1):104-9. PubMed ID: 15642212
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneous genetic alterations in ovarian mucinous tumors: application and usefulness of laser capture microdissection.
Takeshima Y; Amatya VJ; Daimaru Y; Nakayori F; Nakano T; Inai K
Hum Pathol; 2001 Nov; 32(11):1203-8. PubMed ID: 11727259
[TBL] [Abstract][Full Text] [Related]
20. [ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization].
Zhong M; Li J; Ding YQ; Song LL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Dec; 23(6):665-7. PubMed ID: 17160949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
